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Introduction
Multiple sclerosis (MS) is a major, often disabling, neuro-
logical disease affecting young adults.1 The damage to the 
central nervous system (CNS) results from inflammation 
and neurodegeneration, but the definition of what triggers 
and sustains both mechanisms, within or outside the CNS, 
remains incomplete. Structural and quantitative changes in 
myelin proteins may support the pathogenesis of the disease 
through various mechanisms, including an autoaggressive 
immune response to myelin.2,3 Individuals with MS show a 
diffuse hypomethylation of the genome in the white matter.3 
This reprogramming of the DNA methylation pattern may be 
dangerous as, apart from inducing genome destabilization, it 
can reactivate genes that should remain silent in the brain.4-6 
In this scenario, an example of gene reactivation dependent 
on DNA methylation pattern is peptidylarginine deiminase 2 
(PAD2), whose promoter has been found to be less 
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Abstract
Background: Peptidylarginine deiminase 2 (PAD2) and peptidylarginine deiminase 4 (PAD4) are two members of PAD 
family which are over-expressed in the multiple sclerosis (MS) brain. Through its enzymatic activity PAD2 converts 
myelin basic protein (MBP) arginines into citrullines – an event that may favour autoimmunity – while peptidylarginine 
deiminase 4 (PAD4) is involved in chromatin remodelling.
Objectives: Our aim was to verify whether an altered epigenetic control of PAD2, as already shown in the MS brain, 
can be observed in peripheral blood mononuclear cells (PBMCs) of patients with MS since some of these cells also syn-
thesize MBP.
Methods: The expression of most suitable reference genes and of PAD2 and PAD4 was assessed by qPCR. Analysis of 
DNA methylation was performed by bisulfite method.
Results: The comparison of PAD2 expression level in PBMCs from patients with MS vs. healthy donors showed that, as well 
as in the white matter of MS patients, the enzyme is significantly upregulated in affected subjects. Methylation pattern analy-
sis of a CpG island located in the PAD2 promoter showed that over-expression is associated with promoter demethylation.
Conclusion: Defective regulation of PAD2 in the periphery, without the immunological shelter of the blood–brain 
barrier, may contribute to the development of the autoimmune responses in MS.
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methylated in the white matter of subjects with MS.3 This 
was suggested as the mechanism leading to the over-expres-
sion of the enzyme, with a consequent increase of citrullines 
on myelin basic protein (MBP), the best substrate of PAD2 
and a putative autoantigen in MS. Citrullinated isoforms of 
MBP may reduce the stability of myelin3,6,7 and may threaten 
the maintenance of the immunological tolerance to MBP. 
However, it is unclear how changes of this kind, occurring 
behind the blood–brain barrier, may lead to the immuniza-
tion against myelin autoantigens. One possibility may be a 
priming against a citrullinated MBP in the periphery. Since 
MBP is indeed also expressed in lymphoid tissues,8 we veri-
fied whether an altered epigenetic control of PAD2, as 
already shown in the MS brain, can be observed in periph-
eral blood mononuclear cells (PBMCs) of patients with MS. 
We extended the analyses to the peptidylarginine deiminase 
4 (PAD4) gene, another member of the PAD family, which 
codes for an enzyme involved in chromatin remodelling9,10 
and is highly expressed in the brain of patients with MS.11 
Moreover, like PAD2, PAD4 is expressed in peripheral blood 
cells and is able to deiminate MBP arginine residues.11-13
Subjects and methods
Patients and healthy donors
We analysed freshly isolated PBMCs from 32 patients with 
definite MS and from 30 healthy volunteers (50% women). 
All affected individuals were treatment naïve. All samples 
were drawn at least 3 months after the last steroid therapy. 
A contrast-enhanced magnetic resonance imaging (MRI) 
scan was obtained in MS patients within 24 h from sam-
pling. Demographic and clinical details of MS patients are 
summarized in Table 1.
Procedures
PBMCs were obtained by gradient centrifugation through 
‘Lymphoprep’ solution (Axis-Shield). RNA (from 3 × 106 
cells) was isolated by TRIZOL reagent (Invitrogen) 
adopting the manufacturer’s protocol, and quantified by 
NanoDrop (NanoDrop Technologies). RNA quality was 
evaluated by capillary chip electrophoresis using the 
Agilent 2001 Bioanalyzer (Agilent Technologies). Reverse 
transcription and quantitative Taqman RT-PCR were car-
ried out as reported previously.14 The following TaqMan 
Gene Expression Assays IDs for PAD2 and PAD4 were 
used: Hs00247108_m1 and Hs00202612_m1. DNA meth-
ylation analysis of the PAD2 promoter was performed by 
bisulfite sequencing using previously reported primers.15
Statistical analysis
Expression data were analysed by two different statistical 
algorithms: geNorm and NormFinder.16,17 GeNorm uses an 
algorithm to calculate the M value, a gene expression sta-
bility measure, defined as the mean pairwise variation for a 
given gene compared with the remaining tested genes. 
Hence, a lower value of M indicates higher stability of the 
reference gene. We considered 1.5 as a cut-off for the 
M value; genes with an M value above this value are con-
sidered unreliable for normalization. The programme also 
establishes a rank order of gene stability via stepwise exclu-
sion of the least stable gene, which allows identification of 
the remaining two genes with the lowest M value. To deter-
mine how many reference genes should be used for accu-
rate normalization, geNorm also performs a stepwise 
calculation between sequential normalization factors (NF). 
It starts to calculate the pairwise variation V2/3 between the 
NF2 (including the two most stable reference genes) and 
the normalization factor NF3 (including the three most sta-
ble reference genes). It then performs a stepwise calcula-
tion of the Vn/n+1 between the NFn and the NFn+1. A 
variation of the Vn/n+1 above 0.15 indicates that the inclu-
sion of an additional reference gene is required.
NormFinder provides a ranking of the tested genes based 
on a direct measure of both the overall variation of expres-
sion of candidate reference genes in the samples group and 
the variation between samples subgroups. The combined 
measure of intra- and inter-group variation is given as a 
stability value, which is an estimation of the variation in 
expression of candidate reference genes. Low stability val-
ues define genes showing high stability of expression. In 
our settings the intra-group variation is calculated across all 
samples, while the inter-group is calculated between the 
control and MS groups of samples.
We adopted Pearson product-moment correlation coef-
ficient (r) in order to obtain a quantitative estimation about 
a possible linear dependency among gene expression and 
associated clinical data.
Results
Choice of the most suitable reference genes
In order to perform gene expression analysis on PBMC sam-
ples derived from patients with MS we first searched for a 
reference gene suitable for normalization. We selected gene 
Table 1. Demographic and clinical data of patients with 
multiple sclerosis
Number 32
Female/Male 22/10
Age (years) 36.6 (9.6)
Disease-type 31 RR; 1 SP
Disease duration (range-years) 0.1–18
EDSS median (range) 1.5 (1–2)
MRI 28 inactive; 4 active
Disease-modifying therapies None
RR, Relapsing–remitting; SP, Secondary progressive; MRI, magnetic 
resonance imaging; EDSS, Expanded Disability Status Scale
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transcripts with different physiological roles (Table 2) to 
minimize the risk of the MS affecting all of the genes tested. 
The non-normalized expression levels showed normal distri-
bution (Shapiro–Wilk test). 18s rRNA and ACTB showed a 
significant downregulation in MS samples, while the expres-
sion of the other candidate reference genes remained compa-
rable between normal and MS samples (Figure 1A).
We applied two different statistical algorithms, NormFinder 
and geNorm, to the same data set to evaluate the most stable 
reference genes. As shown in Figure 1B, GUSB presented the 
highest stability in the ranking of candidate housekeeping 
genes according to NormFinder analysis.
As the NormFinder analysis could be affected by sam-
pling errors which enhance experimental component of 
variation, to gain an unbiased estimation of the stability of 
the selected candidate reference genes, geNorm algorithm 
was also adopted. It is based on the assumption that the ratio 
between two putative reference genes is nearly constant 
across samples independently of RNA amount analysed per 
sample. The ranking of the tested genes according to 
geNorm expression stability value (M) indicated GUSB and 
HPRT1 as the most stable pair of genes (Figure 1C). The use 
of more than the two most stable reference genes identified 
(GUSB and HPRT1) was not required (Figure 1D).
Gene expression profiling in PBMCs
Over-expression of the PAD2 gene is believed to be one of 
the factors involved in MS disease. We assessed the expres-
sion level of this gene in PBMCs of healthy and MS subjects 
by qRT-PCR to verify whether the upregulation of the PAD2 
gene, observed in the brain of patients affected by MS, could 
Table 2. Panel of candidate reference genes evaluated in  
this study
Symbol Gene name TaqMan assays ID
GUSB Glucuronidase β Hs99999908_m1
ACT Actin β 4333762
HPRT1 Hypoxanthine guanine 
phosphoribosyl transeferase 1
Hs99999909_m1
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase
Hs99999905_m1
18S 18s rRna Hs99999901_m1
Figure 1. Expression stability of candidate reference genes
(A) Expression levels of candidate genes starting from equal amounts of RNA obtained from peripheral blood mononuclear cells (PBMCs) of healthy 
and multiple sclerosis (MS) subjects are shown as medians (horizontal line), 25th to 75th percentile (boxes) and range (whiskers). *p ≤ 0.05
(B) Expression stability value calculated by NormFinder for each candidate reference gene comparing normal vs. MS samples.  A lower value indicates 
higher expression stability.
(C) Selection of the best pair of candidate reference genes for accurate normalization by geNorm.  The average expression stability M of candidate 
reference genes during stepwise exclusion of the least stable gene is shown. The X-axis indicates genes ranked according to their expression stability 
measure. The Y-axis indicates the average M-value of the remaining genes after having excluded the indicated genes (i.e. the less stable).
(D) Pairwise variation between two sequential normalization factors (NFn and NFn+1) to determine the optimal number of reference genes for  
reliable normalization.
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be also evident in blood cells. Analysis was extended also to 
PAD4, another member of PAD family whose level is 
increased in the brain white matter of patients with MS.11
As shown in Figure 2A, we evidenced a significant 
increase in PAD2 mRNA levels in patients with MS com-
pared with healthy donors only after normalization with the 
most stable housekeeping genes or with their geometric 
mean as predicted by both NormFinder and geNorm analy-
sis. This is the first evidence reporting that PAD2 mRNA is 
also upregulated in mononucleated blood cells. The analy-
sis of PAD4 expression did not reveal any significant 
change (Figure 2B).
Methylation profiling of PAD2 promoter in 
PBMCs
Demethylation of CpGs located in the promoter of PAD2 
gene (Figure 2C) is considered the principal event in 
Figure 2. PAD2 and PAD4 expression in normal and multiple sclerosis peripheral blood mononuclear cell samples and methylation 
profiling of PAD2 promoter
PAD2 (A) and PAD4 (B) expression measured by qRT-PCR normalized by single or multiple reference genes as indicated by geNorm and NormFinder 
(mean ±C.V.).
(C) Graphical representation of the CpG island (grey line) in the promoter region of PAD2. Numbers indicate the distance in base pairs from the first 
codon; dashes: CpG dinucleotides.
(D) The methylation state of PAD2 promoter region was evaluated by bisulfite sequencing. Up to 10 independent clones for two multiple sclerosis 
(MS) and two control samples (H) were analysed by the sequencing procedure. Each row of circles represents the sequence of an individual clone. 
Open circle, unmethylated CpG site; filled circle, methylated site.
Figure 3. Pearson product-moment linear coefficient analysis of 
the relation between PAD2 expression and Expanded Disability 
Status Scale (EDSS). r = correlation coefficient, p < 0.05
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inducing the upregulation in the brains of patients with 
MS.3 We verified by bisulfite sequencing whether demeth-
ylation also occurred on the PAD2 promoter in the PBMCs 
of MS patients. The analyses, performed on a DNA frag-
ment of about 400 bp containing 48 CpGs, were carried out 
on two randomly chosen MS patients compared with 
healthy donors matched for gender and age. As shown in 
Figure 2D, the PAD2 promoter region of MS patients was 
extensively demethylated, supporting the observed PAD2 
gene upregulation. We note that the analysis of the methyla-
tion patterns of healthy donors showed that methylation 
was present only in a part of the examined clones.
Correlation between PAD2 gene expression 
profiling and clinical data
We evaluated the Pearson product-moment coefficient in 
order to assess a possible correlation between PAD2 expres-
sion level and clinical data available, in terms of disease 
duration (DD), Expanded Disability Status Scale (EDSS), 
and MRI activity (as reported in Table 1). We observed no 
linear correlations analysing the entire patient population 
available, and additionally, no correlations were found par-
titioning the sample according to the gender.
We further looked into the data in order to investigate 
whether a subset of patients might exist where the linear 
correlation hypothesis might hold. We identified a subset of 
patients (n = 19) with inactive MRI, EDSS value < 2, and 
not containing the two worst data outliers. With respect to 
this subset, which is 63% of the patients, we observed a 
medium correlation between PAD2 levels and EDSS (the 
correlation coefficient is 0.47 and its associated p-value is 
0.02), as reported in Figure 3.
Discussion
PAD2 and PAD4, two members of PAD family18 drew our 
attention as they were found present in a higher quantity in 
the CNS white matter of patients with MS vs. healthy indi-
viduals.11 The high level of PAD2 expression is not present 
in other neuropathologies,3 suggesting an alteration that 
may be specific for MS. In accord with this possibility, MBP 
is the best PAD2 substrate. PAD2 and PAD4, converting 
arginine into citrulline, insert a post-synthetic modification 
onto their protein substrates.18 The decreased positive charge 
on MBP, that follows the citrullination reaction, destabilizes 
the interaction between the lipid bilayer and myelin, and 
affects myelin structure.3,6,7 This excessive deimination of 
MBP changes the protein’s three-dimensional structure, 
increasing its susceptibility to some proteases.19 This pro-
cess may enhance the production of citrullinated epitopes, 
with an intrinsic risk of a breakdown of the immunological 
tolerance to MBP. Indeed, citrullinated MBP peptides can 
induce and sustain inflammation in experimental autoim-
mune encephalomyelitis (EAE).20 However, it is unclear 
how the production of such modified epitopes, occurring 
behind the blood–brain barrier, can lead to a sensitization of 
the immune system in the periphery. Previous work has 
demonstrated that there are opportunities for this to happen: 
during EAE the expression of MBP is increased in lymphoid 
tissue,21 and patients with MS may have an enhanced T-cell 
reactivity to citrulline-containing MBP.22
Despite the limited sample size, here we show that in 
PBMC from patients with MS, the hypomethylation of the 
PAD2 promoter seems to account for the increased ‘periph-
eral’ PAD2 expression. This event may set the stage for an 
increased reactivity or ‘epitope spreading’ towards citrulli-
nated MBP sequences. In this context it is interesting to 
note that the increased PAD2 expression in the PBMCs of 
patients with MS may not be mirrored by a similar upregu-
lation in the thymus,15 hence favouring an imbalance 
between the probabilities of tolerization vs. those of immu-
nization. Finally, citrullinated MBP epitopes may be more 
potent than non-citrullinated ones in inducing a pro-inflam-
matory TH1 polarization in patients with MS.23 On the 
other hand, the humoral IgG response to citrullinated MBP 
does not seem to discriminate patients from controls.24 
Unless a subgroup of MS patients with positive IgG 
responses to citrullinated epitopes is identified in larger 
studies, the reactivity to such targets, in the B-cell compart-
ment, does not repeat the findings in rheumatoid arthritis 
(RA) where antibodies to citrullinated peptide antigens dis-
criminate two major subsets of patients with some differ-
ences also in aetiological features.25
Concerning PAD4, recent findings show that this iso-
form is also upregulated in myelin in MS brain, and is able 
to catalyze MBP deimination in vitro,11 suggesting a possi-
ble contribution of PAD4, together with PAD2, in the 
increase of citrullinated MBP in MS. These data and the 
fact that PAD4 is highly expressed in lymphoid tissues12,13 
together with MBP,8 provided the rationale for determining 
its expression in PBMC from MS patients. Our results, 
showing the selective increase in PAD2 expression, confer 
more specificity to our findings, which thus point to a dis-
tinctive involvement of PAD2.
The role of PAD4 could be different, as its main sub-
strates are H3 and H4 histone proteins9,10 in the nuclei, and 
recent data suggest that PAD4 activity is involved in the 
repression of gene transcription by stabilizing the histone 
H2A/H2B dimer.26
Our data add a new element to the hypothesis of a role for 
the immune response to citrullinated myelin epitopes in the 
pathogenesis of MS. Further work on this topic is highly war-
ranted, not only because of the analogies with RA, where this 
kind of reactivity represents a major pathogenetic (and diag-
nostic) component, but also considering the increasing 
awareness about the potential importance of epigenetic 
mechanisms in the pathogenesis of multifactorial diseases.27
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